Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26199212 | 0.94 | USP2 (0.32) | SMN1; SMN2HPGDHTT | |
| SCHEMBL26199218 | 0.90 | MEN1 (0.32) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL18532465 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL22202997 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL12197747 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL13056639 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL8635388 | 0.88 | PSMB8 (0.32) | SMN1; SMN2HPGDHTTKMT2APSMB8 | |
| SCHEMBL13248325 | 0.87 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL19170723 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2HPGDHTTMEN1KMT2A | |
| SCHEMBL13468979 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2HPGDHTTKMT2APSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | EXPANSION TECHNOLOGIES (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | DCLRE1A, ACR, PHAX | SMN1; SMN2 2572/4885HPGD 3760/4885HTT 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.